I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title. My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative. Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
Long/short biotech investment ideas with a focus on oncology/infectious disease/immunology.
Postings on this site are my own and do not represent the positions, strategies, or opinions of my employer.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
John H. Cochrane is the AQR Capital Management Distinguished Service Professor of Finance at the University of Chicago Booth School of Business. His recent finance publications include the book Asset Pricing, and articles on dynamics in stock and bond markets, the volatility of exchange rates, the term structure of interest rates, the returns to venture capital, liquidity premiums in stock prices, the relation between stock prices and business cycles, and option pricing when investors can’t perfectly hedge. His monetary economics publications include articles on the relationship between deficits and inflation, the effects of monetary policy, and on the fiscal theory of the price level. He has also written articles on macroeconomics, health insurance, time-series econometrics and other topics. He was a coauthor of The Squam Lake Report. He writes occasional Op-eds, and blogs as “the Grumpy Economist” at johnhcochrane.blogspot.com.
Cochrane is a Research Associate of the National Bureau of Economic Research and past director of its asset pricing program, a Senior Fellow of the Hoover Institution at Stanford University, and an Adjunct Scholar of the CATO Institute. He is a past President and Fellow of the American Finance Association, and a Fellow of the Econometric Society. He has been an Editor of the Journal of Political Economy, and associate editor of several journals including the Journal of Monetary Economics, Journal of Business, and Journal of Economic Dynamics and Control.
Recent awards include the TIAA-CREF Institute Paul A. Samuelson Award for his book Asset Pricing, the Chookaszian Endowed Risk Management Prize, and the Faculty Excellence Award for MBA teaching.
Cochrane currently teaches the MBA class “Advanced Investments” and a variety of PhD classes in Asset Pricing and Monetary Economics.
Cochrane earned a Bachelor’s degree in Physics at MIT, and earned his Ph.D. in Economics at the University of California at Berkeley. He was at the Economics Department of the University of Chicago before joining the Booth School in 1994, and visited UCLA Anderson School of Management in 2000-2001.
In addition to research and teaching, Cochrane is a competition sailplane pilot and windsurfs. He lives in Chicago with his wife Elizabeth Fama and children Sally, Eric, Gene and Lydia.
For more information, please see Cochrane’s website, http://faculty.chicagobooth.edu/john.cochrane/
Volte-Face Investments represents the writings of an independent investment manager who managed a long/short equity fund. The author worked for a major Wall Street firm for 12 years before leaving to start his own business in 2009. Since then he has been pursuing investment management full time. The purpose of the articles is to explain the thinking with regards to a particular investment opportunity and to provide readers with a foundation from which they can begin their own due diligence. Volte-Face Investment's writings are not solicitations to transact any security. For further information or consulting, please contact directly via direct message or direct message on twitter @voltefaceinvest
Hereby I declare that the views expressed in my posts are those of Alp Bugra Basat and do not necessarily reflect the views of my industry partners, research supervisors-collaborators and companies I have invested in.
I like basic science; if it is translated into new treatments. I like the biotechs with cutting-edge science. I don't like PI3K, ras, akt inhibitors. I like antibody-drug conjugates. I like sirtuin. I may not believe in β-amyloid. I really like ivacaftor. I am crazy about talimogene laherparepvec. I love the drugs like eteplirsen.
In addition, I don't fall in love with stocks, it means that my opinions expressed here can change in a milisecond, after I get more info.
A special thank goes to Osman Murat Bastopcu!
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
Lares Capital, a long/short fund that specializes in small caps, option strategies, and low-liquidity equities. The fund invests in both domestic and foreign securities.
You can contact us at email@example.com.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
The resource referenced below can be deceptively inaccurate, though it is the only known site that tracks the performance of stocks written about through Seeking Alpha (when using the S&P 500 as a benchmark):
Important information follows, please click the link below to review it all:
Work presented may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but instead represent only the author's belief regarding future events, many of which, by their nature, are inherently uncertain and outside his control. Except for the author's obligation to disclose material information, the author is not under any obligation (and expressly disclaims any obligation) to update or alter any projections, goals, assumptions, or other statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
No content within the author's work is a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person or purpose. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content of this article may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to specific investment needs. The author is not an investment advisor and is not offering investment advice. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published will not contain a list or description of relevant risk factors. Some of the stocks about which the author has written and writes about have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Any information in the author's work deemed by you to be recommendations may have an effect on their stock prices.
The author's publications are not intended to provide tax, legal, insurance or investment advice, and nothing presented in the author's work should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Seeking Alpha or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.
All information in this report is provided "as is" without warranty, expressed or implied, or representations of any kind to the fullest extent permissible under applicable law, the author will not be liable for the quality, accuracy, completeness, reliability, or timeliness of this information, or for any direct, consequential, incidental, special or punitive damages that may arise out of use of this information by you or anyone else, including but not limited to lost profits, loss of opportunities, trading losses, and damage that may result from any inaccuracy or incompleteness of this information to the fullest extent permitted by law. The author denies liability to you or anyone else under any tort, contract, negligence, strict liability, products liability, or other theory with respect to presentation of information.
The information, opinions, data, quantitative and qualitative statements communicated have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. You recognize that performance data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that such calculations are not guaranteed by these sources, the information providers, or any other person or entity, and may not be complete.
The author writes about and invests in high risk companies, some of which succeed, and some of which go out of business completely, rendering securities, including bonds, preferred stock, common stock, options and other financial derivatives valueless.
The author does not intend to receive any inside information from any of the companies written about.
Investors are encouraged to read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Prescient Investment Analysis is a person. BA, Boston College, Philosophy.
Fincom Investment Partners focuses on mid-stage development and special opportunities in the technology and commodity sectors. Over the past 30 years our President has worked with many of the world's top-tier investors, such as Upfront Ventures, co-founded by Paul Allen and last decade’s #1 performing VC. In addition to developing a proprietary Risk vs. Reward parameter methodology, he has initiated many dozens of successful investments such as a $2 million start-up financing for Petrohawk which became a $15 Billion buyout (BHP 2011). He has been quoted in most the financial press including the WSJ, IBD, Barron’s; and in 1989 hosted “The Venture Capitalist” which aired on (now) CNBC.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
As Managing Editor - Opinion and Analysis, I lead the Seeking Alpha team dedicated to curation of crowdsourced investment research and commentary. My responsibilities are to grow the site's audience, deepen user engagement, and improve editorial processes. I am a CFA charterholder and member of the CFA Society Washington, DC.
James A. Kostohryz has accumulated over twenty years of experience investing and trading virtually every asset class across the globe.
Kostohryz started his investment career as an analyst at one of the US's largest asset management firms covering sectors as diverse as emerging markets, banking, energy, construction, real estate, metals and mining. Later, Kostohryz became Chief Global Strategist and Head of International Investments for a major investment bank. Kostohryz currently manages his own investment firm, specializing in proprietary trading and institutional portfolio management advisory.
Born in Mexico, Kostohryz grew up between south Texas and Colombia, has lived and worked in nine different countries, and has traveled extensively in more than 50 others. Kostohryz actively pursues various intellectual interests and is currently writing a book about the impact of culture on economic development. He is a former NCAA and world-class decathlete and has stayed active in a variety of sports.
Kostohryz graduated with honors from both Stanford University and Harvard Law School.
You can receive custom delivery of all of Mr. Kostohryz's published work on Seeking Alpha, The Street, and other media, as well as exclusive material, by following the link below. It is absolutely free:
You may connect with Mr. Kostohryz via the following social networks:
When connecting, be sure to identify yourself as a Seeking Alpha reader.
10 years of buy-side investment experience.
Disclaimer: Any content on this site is NOT investment, trading, legal, or tax advice, and none of the information available through this website is intended to provide tax, legal, investment or trading advice. Nothing provided through this content whether by the owner or posted by other writers constitutes a solicitation of the purchase or sale of securities/futures. The content on this site is intended for informational purposes only, and should never be used as investment advice. Please do your own research before making any investment decisions.
Gravity Research is an organization composed of financial analysts with experience working at top investment banks and buyside firms as well as industry veterans who are experts in their fields. We engage in careful research on publicly traded companies that we believe offer compelling long or short investment opportunities, and present our best ideas to the public.
Blogger, Self-Made Analyst, Trader, Investor, Crowdfunder and Critical Thinker. Currently, I am looking for a job in the investment space. Job offers are always welcome.
The name "Dutch Trader" refers to The Golden Age. This was a period in Dutch history, roughly spanning the 17th century, in which Dutch trade, science, military and art were among the most acclaimed in the world.
Dutch ships hunted whales off Svalbard, traded spices in India and Indonesia (via the Dutch East India Company) and founded colonies in New Amsterdam (now New York), South Africa and the West Indies. In addition some Portuguese colonies were conquered, namely in Northeastern Brazil, Angola, Indonesia and Ceylon. This new nation flourished culturally and economically, creating what historian Simon Schama has called an "embarrassment of riches". Speculation in the tulip trade led to a first stock market crash in 1637, but the economic crisis was soon overcome.
In 1602 the Dutch East India Company was founded. It was the first-ever multinational corporation, financed by shares that established the first modern stock exchange. This company received a Dutch monopoly on Asian trade and would keep this for two centuries. It became the world's largest commercial enterprise of the 17th century. Spices were imported in bulk and brought huge profits, due to the efforts and risks involved and seemingly insatiable demand.
To finance the growing trade within the region, the Bank of Amsterdam was established in 1609, the precursor to, if not the first true central bank.
My background is Management, Economics and Law. This I studied at Fontys Business School in the Netherlands, with specialization in Banking and Insurance.
My passion is investing, writing, travelling, history, swimming, playing chess and enjoying my family.
I love to analyze companies and sectors and write about it. Main points of interests: China, Biotechnology, Consumer, Energy, Mining, Dividend, OTC Market, Food, Robotics and some other themes.
As an investor I have a bias towards value investing and the markets. All opinions are my own and do not represent the views of my employer.Valuation metrics play an important part of my investment strategies. My investment philosophy is Unloved, Underowned and Undervalued.
One of the best investment quotes is: The key to making money in stocks is not to get scared out of them from Peter Lynch.
Do you have any other business proposals or questions, just write an email to firstname.lastname@example.org
Dutch Trader, The Netherlands================
For the Securities Disclaimer & Disclosure, read:
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
Bioassociate is an Israeli company established in 2008 and operating in the life science arena. Bioassociate provides expertise-based consulting, research and analysis services to international life science companies and investment entities (investment banks, private and institutional investors). Visit our website at www.bioassociate.com.
Retail Investor, Shareholder Advocate and Editor of Stocks DD blog. You are cautioned to read the disclaimer in Seeking Alpha before reading my articles. I am NOT a registered investment adviser. My articles are ONLY for informative purposes and should NOT be treated as investment advice.
My investment philosophy:
1. Invest in Strong businesses (high barriers to entry) 2. Invest in Management with excellent track record for shareholder value creation 3. Invest at undervalued prices
Invest in special situations (bankruptcy or other restructuring) or Drug development firms, where there is with an asymmetric reward/risk...where I have strong conviction on a reward event.
I am also interested in the shareholders topics in publicly listed companies:
1. Shareholder rights 2. Giving shareholders a voice incl shareholder participation in value creation 3. Improving board and management's accountability to shareholders
Be a shareholder advocate and work towards insuring boards and management "do the right thing for shareholders", maximizing and protecting shareholder's value.
More on my ideas can be found here:
Mr. Barac is the founder and Managing Member of the General Partner, Barac Capital Management, LLC. Prior to founding the General Partner, Mr. Barac held a variety of roles in institutional securities research and trading.
Mr. Barac graduated from Trinity University (San Antonio, Texas) in 1989 and received a Master’s in Business Administration degree from Southern Methodist University (Dallas, Texas) in 1998. During his graduate studies, Mr. Barac’s broad-based business studies included a focus on international business which included an internship with Bank Boston’s media and telecommunications lending group in Buenos Aires, Argentina and an international exchange semester at the E.S.A.D.E. Business School in Barcelona, Spain.
Following his graduate studies, Mr. Barac went to work for Moody’s Investors Services in New York, New York in 1998 and transferred to their London, England offices in 1999. At Moody’s, Mr. Barac became a Senior Credit Officer/Vice-President and lead analyst with responsibility for the credit ratings of a multi-billion dollar portfolio of high-profile European leveraged finance companies. As an expert in leveraged finance and corporate credit risk analysis, Mr. Barac was a regular speaker for Moody’s and was regularly quoted by major financial publications (e.g. the Wall Street Journal Europe, Financial Times, New York Times, Bloomberg News, and The Times of London).
From 2005 to 2007, Mr. Barac worked at Schroders Investment Management, an investment management firm with assets under management in excess of $200 billion, headquartered in London, England. At Schroder’s, Mr. Barac was responsible for identifying profitable fixed-income trade ideas from within a portfolio of European high-yield and investment grade corporate bond issuers. Mr. Barac’s work at Schroder’s earned him selection for the company’s elite merit-based Business Leadership Program.
Mr. Barac continued his work in corporate securities analysis with Barclay’s Capital (also in London, England) where he worked as a Director in their Principal Strategies Group from 2007 to 2008. At Barclays, Mr. Barac was a proprietary analyst and trader responsible for investing a portion of Barclay’s capital through a combination of bonds, stocks, and fixed-income derivatives (credit default swaps).
Following his return from London to Austin, Texas in 2008, Mr. Barac founded, established, and now actively manages the Barac Value Fund, L.P.
I am a former hedge fund portfolio manager that trades for my own personal account. I espouse Graham and Dodd/Buffett style investing, always on the lookout for value equities or bonds. A graduate of Northwestern's Kellogg School of Management, I lived in NYC for a decade before relocating with my family to the Charlotte, NC area in 2007.
Author of the value investing newsletter detailing the formation of the "Punch Card Portfolio" (http://valueinvestorcanada.blogspot.com/). Devon Shire is an accountant and an investor with 15 years experience managing a private portfolio. Devon Shire's preferred portfolio management style is a concentrated approach, investing only when finding opportunities that offer a sufficient discount to the intrinsic value of a business. Devon can be contacted at email@example.com.
Josh Young is the Chief Investment Officer of Bison Interests, an investment firm focused on publicly traded oil and gas companies. He is a value investor primarily focused on energy stocks, natural resources stocks, and companies trading a low multiples to earnings, cash flow, or book value. He previously served on the board of a small cap publicly traded oil and gas company. He has presented at numerous investment conferences, including Platts, LD Micro, Oil & Gas Money, Louisiana Energy Conference, and the Global Resources Investment Conference.
Daniel Moore is the creator of FinancialRelativity.com, a web portal created for the purpose of tracking the status of financial markets and providing investment analysis and portfolio management insights to investors. Based on the systematic investment research, he writes about the market and publishes his views through internet market publications. He has over 25 years of management experience in corporate finance in a variety of high technology start-ups and public companies. A graduate of Duke University’s Fuqua School of Business in 1988, he has spent the last 10 years managing investment portfolios seeking high risk reward returns for fixed income investors.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
The Atlanta Fed's macroblog provides commentary on economic topics including monetary policy, macroeconomic developments, financial issues and Southeast regional trends. Authors for macroblog are Dave Altig and other Atlanta Fed economists.